CA2688469A1 - 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy - Google Patents

2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy Download PDF

Info

Publication number
CA2688469A1
CA2688469A1 CA002688469A CA2688469A CA2688469A1 CA 2688469 A1 CA2688469 A1 CA 2688469A1 CA 002688469 A CA002688469 A CA 002688469A CA 2688469 A CA2688469 A CA 2688469A CA 2688469 A1 CA2688469 A1 CA 2688469A1
Authority
CA
Canada
Prior art keywords
imidazo
pyridine
dichlorophenyl
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002688469A
Other languages
English (en)
French (fr)
Inventor
Graham Michael Wynne
Peter David Johnson
Paul Damien Price
Cristina Lecci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin IGA Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2688469A1 publication Critical patent/CA2688469A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002688469A 2008-05-22 2009-05-22 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy Abandoned CA2688469A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0809314.8A GB0809314D0 (en) 2008-05-22 2008-05-22 Compounds for treating muscular dystrophy
GBGB0809314.8 2008-05-22
PCT/EP2009/003645 WO2009141159A1 (en) 2008-05-22 2009-05-22 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy

Publications (1)

Publication Number Publication Date
CA2688469A1 true CA2688469A1 (en) 2009-11-26

Family

ID=39615915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002688469A Abandoned CA2688469A1 (en) 2008-05-22 2009-05-22 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy

Country Status (6)

Country Link
EP (1) EP2293793A1 (de)
JP (1) JP2011520934A (de)
AU (1) AU2009238270A1 (de)
CA (1) CA2688469A1 (de)
GB (1) GB0809314D0 (de)
WO (1) WO2009141159A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
MX2009000235A (es) * 2006-07-07 2009-01-23 Gilead Sciences Inc Compuesto de piridazina novedoso y uso del mismo.
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
GB0809314D0 (en) 2008-07-02
AU2009238270A1 (en) 2009-12-10
JP2011520934A (ja) 2011-07-21
EP2293793A1 (de) 2011-03-16
WO2009141159A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
US20100305120A1 (en) Compounds for treating muscular dystrophy
WO2010086040A1 (en) Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010020432A8 (en) Compounds for treatment of duchenne muscular dystrophy
WO2010069684A1 (en) Compounds for treatment of duchenne muscular dystrophy
WO2010057833A1 (en) Compounds for treatment of duchenne muscular dystrophy
EP3072890B1 (de) Pyrimidinyl- und 1,3,5-Triazinylbenzimidazole und ihre Verwendung in der Krebstherapie
US7410966B2 (en) Use of and some novel imidazopyridines
AU2013205240B2 (en) 3,5-diaminopyrazole kinase inhibitors
ES2922080T3 (es) Métodos y composiciones de inhibición de la interacción de DCN1-UBC12
JP2012521983A (ja) ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
BRPI0806811A2 (pt) derivados de purina
CN103619841A (zh) 杂芳基化合物及其使用方法
US9273005B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
US20200383984A1 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
EP2611794A1 (de) 4--azolylaminochinazolinderivate und verwendungsverfahren dafür
US20240174643A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
JP2020531574A (ja) 化合物、その医薬組成物及びその使用及び応用
US20210052525A1 (en) Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2010112093A1 (en) Benzoxazoles for the treatment of duchenne muscular dystrophy
CA2688469A1 (en) 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy
US20240197888A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2010112092A1 (en) Compounds for treatment of duchenne musculary dystrophy
RU2518076C1 (ru) Новое производное индазола или его соль и промежуточное соединение для их получения, а также антиоксидант с их использованием, и применение производных индазола или его соли
WO2010112091A1 (en) Compounds for treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20120522